

Application No.: 10/003,496
Filed: Nov. 1, 2001
Page 3 of 12

Attorney Docket No: 0218us210

Listing of Claims:

The following listing of claims replaces all prior versions and listings of claims in the application. Additions are indicated by underlining and deletions are indicated by ~~strikethrough~~, except where a strikethrough would not be easily perceived, in which case the deleted text is indicated by double brackets [[]] flanking the text to be deleted.

1. (Amended) A single-chain multimeric polypeptide having G-CSF activity, comprising at least two monomeric units independently selected from (a) hG-CSF with the amino acid sequence shown ~~in as set forth in SEQ ID NO:1~~ and (b) a variant[[s]] of hG-CSF ~~with an amino acid sequence which differs in 1-8 amino acid residues from SEQ ID NO:1 and which comprises at least one amino acid residue modification selected from the group consisting of: introduction of a lysine, cysteine, aspartic acid, glutamic acid or histidine residue, and removal of a lysine, cysteine, aspartic acid, glutamic acid or histidine residue,~~ said monomeric units being linked via a peptide bond or a peptide linker ~~linker peptide~~, the polypeptide comprising at least one covalently bound polymer molecule selected from the group consisting of a linear polyalkylene oxide and a branched polyalkylene oxide[[s]].
2. (Original) The single-chain multimeric polypeptide of claim 1, wherein the polymer molecule is polyethylene glycol.
3. (Original) The single-chain multimeric polypeptide of claim 2, wherein at least one polyethylene glycol molecule is bound to a lysine residue.
4. (Amended) The single-chain multimeric polypeptide of claim 1, wherein at least one of said monomeric units has the amino acid sequence of hG-CSF ~~(SEQ ID NO:1) as set forth in SEQ ID NO:1~~.

Application No.: 10/003,496
Filed: Nov. 1, 2001
Page 4 of 12

Attorney Docket No: 0218us210

5. (Amended) The single-chain multimeric polypeptide of claim 4, comprising two monomeric units, wherein ~~both~~each of said monomeric units ~~have~~has the amino acid sequence of hG-CSF (SEQ ID NO:1) as set forth in SEQ ID NO:1.
6. (Amended) The single-chain multimeric polypeptide of claim 1, wherein at least one of said monomeric units is a variant of hG-CSF comprising ~~at least one substitution, addition or deletion compared to SEQ ID NO:1 according to (b)~~.
7. (Canceled)
8. (Amended) The single-chain multimeric polypeptide of claim 6, comprising two monomeric units, wherein ~~both~~each of said monomeric units ~~have~~at least one amino acid residue modification compared to hG-CSF is a variant of hG-CSF according to (b).
9. (Amended) The single-chain multimeric polypeptide of claim 1, comprising two monomeric units, wherein one of said monomeric units has the amino acid sequence of hG-CSF (SEQ ID NO:1) as set forth in SEQ ID NO:1 and the other monomeric unit is a variant of hG-CSF according to (b).
10. - 21. (Canceled)
22. (Amended) A nucleic acid comprising a nucleotide sequence encoding a ~~the~~ single-chain multimeric polypeptide according to claim 1.
23. (Amended) An expression vector comprising ~~a~~ the nucleic acid nucleotide sequence according to claim 22.
24. (Amended) A recombinant host cell comprising ~~an~~ the expression vector according to claim 23.

Application No.: 10/003,496
Filed: Nov. 1, 2001
Page 5 of 12

Attorney Docket No: 0218us210

25. (Amended) A method for preparing a single-chain multimeric polypeptide having G-CSF activity, comprising culturing a recombinant host cell according to claim 24 comprising a single nucleotide sequence encoding said polypeptide comprising the expression vector of claim 23 in a suitable culture medium under conditions permitting expression of the nucleotide sequence, and nucleic acid, recovering the resulting polypeptide from the cell culture, and subjecting the polypeptide to conjugation with a polymer molecule selected from the group consisting of a linear polyalkylene oxide and a branched polyalkylene oxide.
26. (Amended) The method of claim 25, further comprising subjecting the polypeptide to conjugation in-vitro with a non-polypeptide moiety under suitable reaction conditions to result in a polypeptide conjugate wherein the polymer molecule is a polyethylene glycol.
27. (Amended) A composition comprising a single-chain multimeric polypeptide according to claim 1 together with and at least one excipient or vehicle.
- 28.- 33. (Canceled)
34. (New) A method for treating a mammal exhibiting leukopenia or neutropenia, comprising administering to said mammal an effective amount of the single-chain multimeric polypeptide of claim 1.